Tacrolimus — How Dangerous It Is, Side Effects and Kidney Damage

EFFECTIVE | TOXIC

Under What Names Is Tacrolimus Available

The international nonproprietary name is tacrolimus; it is also referred to as tacrolimus monohydrate and by its former research designation FK506. Systemic formulations are available as immediate-release and prolonged-release capsules, granules for oral suspension, and solutions for intravenous administration. The main trade names include Prograf, Advagraf, Envarsus, Envarsus XR, Astagraf XL, Modigraf, and Tacforius. Topical formulations are available as 0.03% and 0.1% ointments under the name Protopic and other regional brands. Immediate-release and prolonged-release formulations are not interchangeable milligram for milligram: accidental substitution can result in toxic concentrations or inadequate immunosuppression and transplant rejection. Standard fixed combinations of tacrolimus with other active substances are practically nonexistent; however, after transplantation it is commonly used together with glucocorticosteroids, mycophenolate, or azathioprine.

Why Tacrolimus Is Perceived as a Familiar Medicine and Where the Real Risk Begins

Tacrolimus should not be regarded as an ordinary anti-inflammatory ointment or a standard tablet taken after transplantation. It is a potent calcineurin inhibitor with a narrow therapeutic range: even a small change in absorption, metabolism, liver function, concomitant therapy, or food intake can substantially alter its blood concentration. Insufficient exposure increases the risk of transplant rejection, while excessive exposure primarily causes damage to the kidneys and nervous system. Particularly dangerous situations include switching independently from an immediate-release to a prolonged-release formulation, doubling the dose after a missed dose, changing the timing of administration in relation to food, or combining tacrolimus with substances that inhibit CYP3A4. With systemic tacrolimus, trough blood concentration measurement and laboratory monitoring are mandatory; prescribing it solely according to the “number of milligrams” is pharmacologically inappropriate.

Topical tacrolimus creates a different false sense of security: the absence of hormones is mistakenly interpreted as the absence of serious restrictions. The ointment does not cause the skin atrophy typical of prolonged use of topical glucocorticosteroids, but it suppresses the local immune response, may intensify burning, contribute to infectious complications, and is not intended for uncontrolled continuous application. The FDA maintains a warning for topical calcineurin inhibitors regarding rare cases of lymphoma and skin cancer, while emphasizing that a causal relationship has not been proven and that the long-term safety of continuous use has not been fully established.

Side Effects During the First Hours and Days of Use

With systemic use, early reactions may include tremor, headache, insomnia, paresthesia, nausea, diarrhea, elevated blood pressure, hyperglycemia, hyperkalemia, and deterioration of kidney function. Acute nephrotoxicity is primarily associated with pronounced constriction of the renal blood vessels, reduced renal blood flow, and decreased glomerular filtration. Laboratory findings include increased creatinine and urea, reduced estimated glomerular filtration rate, hyperkalemia, and sometimes hyperuricemia. This type of injury is often reversible if exposure is reduced promptly, but waiting for pronounced symptoms is dangerous: a patient may feel subjectively well even when laboratory parameters have already deteriorated significantly.

Clinically significant neurotoxicity includes severe tremor, confusion, visual disturbances, psychiatric changes, seizures, and posterior reversible encephalopathy syndrome. The risk increases with high drug concentrations, hypertension, hypomagnesemia, impaired kidney function, and interactions that slow tacrolimus metabolism. At the same time, immunosuppression increases susceptibility to bacterial, viral, fungal, and opportunistic infections, including reactivation of the BK and JC polyomaviruses. The latter may lead to transplant nephropathy or progressive multifocal leukoencephalopathy.

For the ointment, the most characteristic reactions are burning, a sensation of heat, itching, tenderness, and redness at the application site, particularly during the first few days. Folliculitis, acne-like eruptions, herpes infection, eczema herpeticum, and increased skin sensitivity to alcohol with facial flushing and burning may occur. Applying the ointment to large areas of inflamed, eroded, or barrier-damaged skin increases systemic absorption.

Consequences of Long-Term or Repeated Use

Chronic nephrotoxicity from tacrolimus is more dangerous than a temporary increase in creatinine. Prolonged constriction of renal blood vessels, toxic tubulopathy, and tubulointerstitial injury may lead to arteriolopathy, interstitial fibrosis, tubular atrophy, and a persistent decline in kidney function. Functional changes may be reversible at an early stage, but established fibrosis cannot be eliminated simply by reducing the dose. At the same time, the absence of elevated creatinine during the first weeks does not exclude gradual damage to renal tissue.

Long-term therapy is also associated with arterial hypertension, hyperkalemia, hypomagnesemia, impaired glucose tolerance, and new-onset diabetes mellitus after transplantation. Persistent tremor, peripheral neuropathy, and other neurotoxic reactions may occur. Immunosuppression increases the probability of severe infections and malignancies, particularly lymphoproliferative disorders and skin tumors; the magnitude of this risk depends on the overall intensity and duration of the entire immunosuppressive regimen, not solely on tacrolimus.

Tacrolimus does not cause drug addiction or classic tolerance. However, abrupt discontinuation of systemic therapy after transplantation can produce an immunological rebound — acute rejection and loss of the transplant. No specific physiological withdrawal syndrome has been established for topical ointment, but atopic dermatitis may recur rapidly after treatment is discontinued because the drug suppresses inflammation rather than eliminating the underlying predisposition to the disease.

Contraindications and High-Risk Groups

Systemic tacrolimus is particularly dangerous in patients with pre-existing impairment of kidney function, severe hyperkalemia, uncontrolled hypertension, nervous system disorders, severe liver dysfunction, or concomitant use of nephrotoxic or neurotoxic drugs. Hepatic insufficiency reduces tacrolimus clearance and may lead to accumulation even at a standard dose. In patients with diarrhea, the drug concentration may sometimes increase paradoxically because of altered intestinal metabolism and transport; therefore, prolonged diarrhea requires an unscheduled measurement of tacrolimus levels.

Closer monitoring is required in elderly patients, people with diabetes mellitus, dehydration, infection, unstable blood pressure, or electrolyte disturbances. Tacrolimus may prolong the QT interval, so the combination of hypokalemia or hypomagnesemia with other agents that affect myocardial repolarization increases the risk of arrhythmias. Live vaccines during systemic immunosuppression may cause infectious complications and are generally contraindicated.

The ointment should not be applied in cases of hypersensitivity to the drug, to areas with active bacterial, viral, or fungal infection, or without special supervision when the skin barrier is severely impaired. It is not intended for application to mucous membranes, under occlusive dressings, or to areas suspected of having premalignant or malignant lesions. In younger children, the permitted concentration and age restrictions depend on national prescribing information.

Dangerous Drug and Food Interactions

The most dangerous interactions involve potent inhibitors of CYP3A4 and P-glycoprotein: clarithromycin, erythromycin, azole antifungal agents including voriconazole, posaconazole, itraconazole, and ketoconazole, certain protease inhibitors, cobicistat, and several calcium channel blockers. These agents can sharply increase tacrolimus concentrations and cause acute nephrotoxicity, hyperkalemia, neurotoxicity, and cardiac rhythm disturbances. Such combinations require dose adjustment in advance, frequent measurement of tacrolimus concentrations, and monitoring of creatinine and electrolytes; prescribing them without monitoring is unacceptable.

Grapefruit and grapefruit juice inhibit intestinal CYP3A and increase tacrolimus exposure, so they should be avoided. Pomelo, Seville orange, and certain concentrated citrus extracts may potentially create a similar risk. Cannabidiol may also increase tacrolimus concentrations and requires a separate interaction assessment.

Rifampicin, rifabutin, carbamazepine, phenytoin, phenobarbital, and St John’s wort induce CYP3A, reduce tacrolimus concentrations, and may provoke transplant rejection. St John’s wort is particularly dangerous because patients often do not regard a herbal preparation as a medicine and may fail to tell their physician that they are taking it.

Cyclosporine should not be used simultaneously with tacrolimus because of increased nephrotoxicity and pharmacokinetic interaction. The risk of kidney damage increases when tacrolimus is combined with aminoglycosides, vancomycin, amphotericin B, certain antiviral drugs, co-trimoxazole, and nonsteroidal anti-inflammatory drugs. ACE inhibitors, angiotensin receptor blockers, potassium-sparing diuretics, and potassium preparations increase the risk of hyperkalemia.

Alcohol is not a direct inhibitor of tacrolimus metabolism, but it may aggravate dizziness, flushing associated with ointment use, dehydration, blood pressure fluctuations, and the burden on the liver. Regular alcohol consumption makes it more difficult to maintain stable drug concentrations and increases the risk of missed doses or accidental repeat dosing.

Patient Errors That Turn Treatment Toxic

The most dangerous mistake is independently changing the dose according to how one feels. Tacrolimus is not dosed according to the presence or absence of symptoms: a toxic concentration may already be damaging the kidneys without causing pain, while a low concentration may not be felt until rejection develops. The next dose must not be doubled after a missed dose, different formulations must not be treated as equivalent, and the manufacturer or administration schedule in relation to food must not be changed without subsequent concentration monitoring.

Common causes of toxicity include starting an antibiotic or antifungal course without informing the transplant specialist, consuming grapefruit, taking NSAIDs for pain, becoming dehydrated during fever or diarrhea, and using potassium or herbal supplements without checking for interactions. An error by a physician or pharmacy when substituting Prograf with Advagraf, Envarsus, or another modified formulation can also alter exposure and lead either to toxicity or rejection. Official prescribing information specifically warns that different tacrolimus formulations should not be substituted without specialist supervision.

Typical errors with topical use include daily application for many months without reassessing the diagnosis, treating infected skin, using the ointment under an occlusive covering, applying it over a very large area, and continuing therapy despite a lack of effect. This may mask an infection, intensify local irritation, or allow another condition that resembles atopic dermatitis to go unrecognized.

Tacrolimus Overdose and Poisoning

No universal toxic dose of tacrolimus has been established. Toxicity is determined not only by the number of milligrams taken, but also by the trough blood concentration, formulation, liver and kidney function, genetically determined CYP3A5 activity, interactions, hematocrit, and time elapsed since transplantation. Therefore, a standard dose may become toxic after clarithromycin, voriconazole, or another potent CYP3A inhibitor is added.

During the first hours, overdose may present with tremor, headache, nausea, vomiting, weakness, confusion, elevated blood pressure, and tachycardia. This may be followed by increased creatinine, reduced urine output, hyperkalemia, pronounced neurotoxicity, seizures, and encephalopathy. The absence of symptoms immediately after an accidental excessive dose does not exclude subsequent kidney damage.

There is no specific antidote. Because tacrolimus binds extensively to erythrocytes and plasma proteins, hemodialysis and hemoperfusion are generally of little benefit. Treatment includes immediate withdrawal or temporary interruption of the drug as directed by a specialist, monitoring of tacrolimus concentration, kidney function, potassium, magnesium, glucose, blood pressure, and ECG, removal of the interacting drug, and supportive treatment. After an accidental extra dose, substitution of the formulation, or development of tremor, confusion, a sharp reduction in urine output, or pronounced weakness, one should not wait until the next scheduled laboratory test.

To prepare the section on an integrative alternative, please provide links or a list of the herbal preparations being considered separately for: the main replacement for topical tacrolimus ointment in inflammatory skin diseases; additional nephroprotective and anti-inflammatory support if systemic tacrolimus after transplantation is to be discussed.

Independent discontinuation or substitution of systemic tacrolimus after transplantation is unacceptable: a herbal preparation cannot replace the immunosuppression required to prevent transplant rejection.

A Safe Integrative Alternative to Topical Tacrolimus

For atopic, eczematous, and allergic skin inflammation, a milder topical alternative that may be considered is an ointment made from extracts of Nigella sativa, Scutellaria baicalensis, and Centella asiatica.

To prepare 100 g of ointment, use 4 g of dry Nigella sativa extract, 4 g of dry Scutellaria baicalensis extract, 3 g of dry Centella asiatica extract, 68 g of coconut oil, 15 g of beeswax, and 6 g of lanolin. Heat the coconut oil, beeswax, and lanolin in a water bath to 55–60 °C. Separately triturate the extracts with a small amount of the warm base until a homogeneous paste forms, then gradually incorporate this into the main mixture. Mix thoroughly, cool to approximately 40 °C, and transfer to a dark glass container.

Nigella sativa provides the main anti-inflammatory and antipruritic component of the combination. Topical Nigella sativa preparations may reduce the severity of eczema, itching, erythema, and inflammatory skin reactions. However, the volume of clinical research remains substantially smaller than that available for tacrolimus, so the ointment cannot automatically be regarded as its complete pharmacological equivalent.

Scutellaria baicalensis complements the effects of Nigella sativa through its baicalin, baicalein, and other flavonoids. These compounds influence pro-inflammatory signaling pathways, mast cell activity, the release of allergy mediators, and cytokine production.

Centella asiatica does not act as a calcineurin inhibitor, but it promotes restoration of the epidermal barrier, epithelialization of fissures, and reduction of residual skin damage. It is particularly appropriate when inflammation is accompanied by dryness, scaling, and disruption of epidermal integrity.

This ointment is more rational for mild or moderate localized inflammation, chronic dryness, itching, and skin barrier damage. In severe widespread atopic dermatitis, it should not be regarded as a guaranteed replacement for tacrolimus.

Before first use, a patch test should be performed on a small area of skin. Herbal extracts, including Nigella sativa and Scutellaria baicalensis, may cause irritation or allergic contact dermatitis. The ointment should not be applied to infected, weeping, eroded surfaces or mucous membranes without prior diagnosis.

In widespread atopic disease with a pronounced allergic phenotype, Allergy Mixture Capsules LH may additionally be considered. It may be used as a component of systemic antiallergic support, but not as a mandatory addition or a direct substitute for topical treatment.

Clerodendrum serratum and Bronchial Asthma Type 2 Capsules LH should be considered only when dermatitis is accompanied by bronchial asthma, respiratory allergy, or other manifestations of type 2 inflammation.

Rhinitis and Rhinosinusitis Mixture Capsules LH is intended for concomitant allergic rhinitis or rhinosinusitis. Including it in the treatment of isolated dermatitis without the corresponding indications is not appropriate.

ABP-153 and ABP-153D are intended for specific local applications involving mucous membranes and ENT organs. They are not universal substitutes for tacrolimus ointment in skin dermatitis.

A completely different approach is required when tacrolimus is taken systemically after transplantation. Neither Nigella sativa, Scutellaria baicalensis, Centella asiatica, nor antiallergic herbal combinations can replace anti-rejection immunosuppression.

Immunomodulatory plants may alter immune system activity or tacrolimus concentrations and thereby increase the risk of toxicity or transplant rejection. Turmeric and curcumin also should not be presented as unconditionally safe nephroprotective support: concentrated preparations may affect CYP3A and P-glycoprotein, which are involved in the metabolism and transport of tacrolimus.

The Real Effectiveness of Tacrolimus and Medical Errors

Systemic tacrolimus is genuinely effective in preventing rejection after kidney, liver, heart, and other organ transplantation. It suppresses calcineurin-dependent activation of T lymphocytes and production of interleukin-2, reducing the intensity of the immune response against the transplant.

In this situation, tacrolimus is not a simple symptomatic treatment. It is one of the key components of anti-rejection therapy, and its benefits may substantially outweigh its toxicological risks. However, this balance is maintained only when drug concentrations in the blood are measured regularly and kidney function is monitored.

Topical tacrolimus is effective in moderate to severe atopic dermatitis, particularly on the face, eyelids, neck, and skin folds, where prolonged use of potent topical glucocorticosteroids is associated with a risk of skin atrophy.

The ointment reduces itching, redness, and inflammatory infiltration and does not cause the typical steroid-related thinning of the skin. At the same time, tacrolimus does not eliminate the underlying predisposition to atopic inflammation and does not treat an infectious, contact, or fungal cause of dermatitis.

In seborrheic, contact, and other forms of dermatitis, the drug is sometimes used outside its principal approved indications. It may temporarily suppress inflammation while at the same time masking continued exposure to an allergen, a bacterial infection, a fungal lesion, or another skin disorder.

Typical medical errors with topical use include prescribing the ointment for an indefinite period without reassessing the diagnosis, applying it to infected skin, failing to evaluate the area involved, and continuing treatment despite a lack of response.

With systemic therapy, particularly dangerous errors include prescribing a fixed dose without monitoring trough concentrations, mechanically substituting one formulation for another, failing to monitor kidney function and electrolytes, and prescribing CYP3A inhibitors or inducers without adjusting the treatment regimen.

Immediate-release capsules, prolonged-release capsules, and other modified tacrolimus formulations must not be substituted automatically on a milligram-for-milligram basis. Such substitution may result either in toxic concentrations or in inadequate immunosuppression and transplant rejection.

Safety Monitoring During Treatment

During systemic therapy, the trough concentration of tacrolimus in whole blood must be measured regularly. The target range depends on the transplanted organ, time since transplantation, concomitant immunosuppression, and the protocol of the particular transplant center.

There is no universal concentration that is equally appropriate for all patients. The higher the tacrolimus exposure, the greater the probability of nephrotoxicity, neurotoxicity, hyperkalemia, and post-transplant diabetes mellitus.

Before treatment and subsequently according to an individualized schedule, creatinine, estimated glomerular filtration rate, urea, potassium, magnesium, blood glucose, liver function parameters, and blood pressure should be monitored.

After any change in dose or formulation, initiation or discontinuation of an interacting drug, development of diarrhea or dehydration, or deterioration of kidney function, the tacrolimus concentration must be measured outside the usual schedule.

An increase in creatinine, a reduction in GFR, hyperkalemia, decreased urine output, new or worsening tremor, severe headache, confusion, visual disturbances, seizures, and a sharp rise in blood pressure require immediate assessment of the drug concentration and review of treatment.

Acute kidney injury associated with high tacrolimus exposure may be reversible after timely dose reduction or temporary discontinuation of the drug. However, established chronic tubulointerstitial injury, tubular atrophy, and fibrosis of renal tissue may remain irreversible.

Fever, persistent cough, shortness of breath, painful urination, shingles, unusual neurological symptoms, and prolonged diarrhea may indicate infection or reactivation of a latent pathogen.

Self-treatment with antibiotics or antifungal drugs in this situation is particularly dangerous. Certain macrolides and azole antifungal agents can sharply increase tacrolimus concentrations and aggravate damage to the kidneys and nervous system.

With topical use, the course of inflammation and the presence of weeping, pustules, vesicles, crusting, and herpetic eruptions should be assessed. If the lesion does not improve, spreads, or rapidly recurs after treatment is stopped, the diagnosis should be reconsidered.

Tacrolimus must not continue to be applied to an infected or unidentified rash. The drug is intended primarily for the treatment of atopic dermatitis and should not be used as a universal ointment for every form of skin redness and itching.

Proper Discontinuation of Tacrolimus

Systemic tacrolimus after transplantation must not be stopped abruptly or reduced independently. It does not cause a classic drug dependence syndrome, but discontinuation of immunosuppression restores T-lymphocyte activity and may lead to acute rejection, damage to, and loss of the transplant.

Even temporarily missing several doses may be clinically significant, particularly during the early postoperative period or in patients with high immunological activity.

Changes to the systemic regimen should be made only by a transplant specialist and a clinical pharmacologist. Gradual dose reduction, transition to another formulation, or switching to another immunosuppressant may be possible, but such decisions are made with consideration of the tacrolimus concentration, transplant status, kidney function, and the entire immunosuppressive regimen.

Substitution of systemic tacrolimus with a herbal immunomodulator is unacceptable.

Topical ointment can generally be discontinued without gradually reducing the amount applied or the frequency of application. No specific physiological withdrawal syndrome has been established for topical tacrolimus.

Inflammation may return after treatment is discontinued because the atopic predisposition and skin barrier impairment remain. Rapid worsening after discontinuation more often represents recurrence of the disease rather than drug dependence.

In patients with frequent recurrences, allergens, infection, occupational irritants, skin barrier abnormalities, and skin-care errors should be investigated rather than automatically restarting indefinite tacrolimus application.

A Rational Approach to Treatment

Systemic tacrolimus is justified after transplantation because its potent and predictable immunosuppressive action prevents organ rejection. In this situation, the toxicity of the drug is not a reason for independent substitution.

The main objective is to achieve the minimum effective concentration, regularly monitor kidney function, and eliminate dangerous drug and herbal interactions.

Topical tacrolimus is justified in moderate to severe atopic dermatitis, particularly on the face, eyelids, and skin folds, and when topical glucocorticosteroids are restricted or poorly tolerated.

The drug genuinely reduces inflammation, but it should not become a universal treatment for every area of red and itchy skin.

For mild or moderate localized inflammation, chronic dryness, skin barrier damage, and absence of infection, an ointment containing extracts of Nigella sativa, Scutellaria baicalensis, and Centella asiatica may be considered.

Its potential advantage lies in the combination of anti-inflammatory, antipruritic, and reparative effects without the systemic immunosuppressive burden characteristic of systemic tacrolimus.

The limitations remain the smaller body of clinical research, the inability to guarantee full equivalence to tacrolimus, and the risk of individual contact allergy.

The goal of an integrative approach is not to mechanically replace an effective medicine with an herbal mixture, but to use potent immunosuppression only when it is genuinely necessary.

For stable and limited skin disease, preference may be given to a topical treatment with a lower toxicological burden. In severe widespread dermatitis or after transplantation, treatment is determined by the clinical situation, the patient’s condition, and objective laboratory monitoring.

If you have questions about the subject of this article, you can ask a clinical pharmacologist in the comments or make an appointment.